Relationship Between Short‐Term Outcomes and PD‐L1 Expression Based on Combined Positive Score and Tumor Proportion Score in Recurrent or Metastatic Head and Neck Cancers Treated With Anti‐PD‐1 Antibody Monotherapy
ABSTRACT Background PD‐L1 expression in tumors and immune cells is a biomarker for the efficacy of anti‐PD‐1 antibody (APA) therapy across diverse cancers. Based on the results from the KEYNOTE‐048 trial, pembrolizumab monotherapy is indicated for platinum‐sensitive recurrent/metastatic head and nec...
Saved in:
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Cancer Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/cnr2.70125 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|